MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Current Ratio 2011-2026 | EXEL
Annual Current Ratio Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.16 | 4.19 | 4.34 | 5.27 | 6.45 | 7.08 | 7.08 | 8.5 | 4.21 | 3.42 | 3.42 | 0.973 | 3.03 | 5.29 | 2.48 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.5 | 0.973 | 4.66 |
Quarterly Current Ratio Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.26 | 4.15 | 4.02 | 4.19 | 4.32 | 4.24 | 4.15 | 4.34 | 4.73 | 5.11 | 5.34 | 5.27 | 6.3 | 5.88 | 7.37 | 6.45 | 7.3 | 7.3 | 7.84 | 9.44 | 8.15 | 9.6 | 9.4 | - | 9.85 | 10.6 | 9.83 | 10.6 | 10.6 | 10.6 | 10.6 | 1.77 | 1.77 | 1.77 | 1.77 | 1.18 | 1.06 | 1.18 | 1.18 | 0.7 | 0.7 | 0.76 | 0.76 | 0.67 | 0.74 | 0.74 | 0.74 | 1.04 | 1.15 | 1.15 | 1.15 | 1.51 | 1.7 | 1.7 | 1.7 | 1.3 | 1.3 | 1.3 | 1.3 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 | 0.67 | 4.23 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
2.84 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.41 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
2.68 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
0.762 | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
3.81 | $ 0.88 | -1.73 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
2.61 | $ 22.6 | 1.32 % | $ 3.75 B | USA |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
0.0929 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
2.88 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
4.56 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
3.56 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.22 | - | 5.93 % | $ 314 M |  Canada |
 |
Galectin Therapeutics
GALT
|
0.134 | $ 2.33 | -1.69 % | $ 149 M | USA |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |
 |
Genmab A/S
GMAB
|
15 | $ 26.81 | 0.62 % | $ 16.8 B |  Danmark |
 |
Aridis Pharmaceuticals
ARDS
|
0.378 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
7.95 | $ 101.78 | -0.27 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
0.372 | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.08 | -0.49 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
1.78 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Heron Therapeutics
HRTX
|
1.06 | $ 1.22 | 2.1 % | $ 203 M | USA |
 |
ImmuCell Corporation
ICCC
|
2.75 | $ 8.43 | 2.12 % | $ 76.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.43 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
0.269 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
15.9 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 2.92 | -0.14 % | $ 4.81 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
1.46 | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |
 |
Kamada Ltd.
KMDA
|
6.58 | $ 8.16 | -0.43 % | $ 260 M | Israel |